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Abstract  
Objective:  
To compare the value that rheumatologists across Europe attach to patients’ preferences and economic 
aspects when choosing treatments for rheumatoid arthritis (RA) patients. 
Methods:  
In a discrete choice experiment European rheumatologists chose between two hypothetical drug 
treatments for a patient with moderate disease activity. Treatments differed in five attributes: efficacy 
(improvement and achieved state on disease activity), safety (probability of serious adverse events), 
patient’s preference (level of agreement), medication costs and cost-effectiveness (incremental cost-
effectiveness ratio (ICER)). A Bayesian efficient design defined fourteen choice sets and a random 
parameter logit model was used to estimate relative preferences for rheumatologists across countries. 
Cluster analyses and latent class models were applied to understand preference patterns across countries 
and among individual rheumatologists. 
Results:  
Responses of 559 rheumatologists from 12 European countries were included in the analysis (49% 
females, mean age 48 years). In all countries, efficacy dominated treatment decisions followed by 
economic considerations and patients´ preferences. Across countries, rheumatologists avoided selecting a 
treatment that patients disliked. Latent class models revealed four respondent profiles: one traded off all 
attributes except safety, and the remaining three classes disregarded ICER. Among individual 
rheumatologists, 57% disregarded ICER and these were more likely from Italy, Romania, Portugal or 
France whereas 43% disregarded uncommon/rare side effects and were more likely from Belgium, 
Germany, Hungary, Netherlands, Norway, Spain, Sweden or United Kingdom 
Conclusion:   
Overall, European rheumatologists are willing to trade between treatment efficacy, patients’ treatment 
preferences and economic considerations. However, the degree of trade-off differs between countries and 
among individuals. 
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Background  
Traditionally, drug treatment decisions for patients with rheumatoid arthritis (RA) were primarily based on 
benefits and risks associated with a drug. Patient´s preferences and treatment costs usually received little 
attention, only [1]. The introduction of biologics has increased treatment opportunities substantially. The 
new treatments are between 20 and 60 times more costly, and therefore raise concerns about affordability 
of RA care [2, 3]. Today, in most European countries, access to biologics is highly regulated [4] . In 
addition to the economic dimension becoming increasingly important, physicians across Europe are 
encouraged to actively involve their patients in treatment decisions. Patient-centered-care is expected to 
improve adherence to agreed treatment plans and thus positively influence health outcomes [5]. However 
it can be a challenge to include patients´ preferences in decisions that are influenced by multiple other 
aspects. 
Although costs and cost-effectiveness (CE) have been given consideration in recent European League 
Against Rheumatism (EULAR) developed treatment recommendations [6, 7] recommendations rely mainly 
on evidence for effectiveness and safety. Optimal patient care across Europe will depend on how 
recommendations are implemented in the context of differences in the economic situations of countries 
and differences in the attitudes of physicians and patients. A recent article revealed a strong association 
between access to (expensive) biologics and the country´s wealth [8]. Interestingly however, another 
review found that drug coverage for innovative and expensive drugs does not necessarily translate into its 
use; there were differences in use between countries with comparable reimbursement criteria, and also 
between regions within a country [9]. Differences in attitudes among clinicians likely contribute to 
differences in treatment choices [10]. 
To our knowledge, limited data exists about the differences in values that rheumatologists attach to 
various treatment characteristics beyond efficacy and safety. Little is known about how rheumatologists 
assess economic consequences of a treatment choice – do they take into account relative CE 
considerations or primarily use absolute costs to make economic trade-offs? Moreover, there is limited 
research on how rheumatologists consider patient´s preferences. 
In this study, we aim to assess if rheumatologists across Europe are willing to trade-off treatment efficacy 
and safety for economic considerations and patients´ preferences. Further, the study aims to determine 
different preference profiles of rheumatologists and whether preference profiles are associated with the 
country rheumatologists are located in.  
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Methods 
A discrete choice experiment (DCE) was designed to investigate relative preferences of rheumatologists 
when choosing drug treatments in RA. In the DCE, rheumatologists were presented with a series of 
choices and asked in each to select the preferred drug treatment among two hypothetical treatment 
options (A or B). The treatment options were described by a set of attributes, further specified by attribute 
levels.  
 
Selection of Attributes and Levels and Patient Profile 
Selection of attributes and levels is fundamental in the design of a reliable DCE study [11, 12]. We 
followed a step wise approach. First, potentially important attributes, attribute definitions and levels were 
identified from literature [11, 13-23]. Second, an expert group (n=6) consisting of rheumatologists and 
experts in the field of economic evaluations, DCE and decision-making agreed on an initial list of 
attributes/definitions/levels. Third, the proposed candidate attributes/definitions/levels were discussed with 
8 rheumatologists from three countries to ensure they reflected clinical realities.  
Five attributes were selected for the DCE: efficacy (status and improvement of disease activity score of 28 
joints (DAS28), safety (risk of a serious adverse event (AE)), patient´ s preference (level of agreement 
with treatment choice), annual drug costs and CE (Incremental Cost-effectiveness Ratio (ICER) compared 
to usual care expressed as incremental cost of one quality adjusted life year (QALY) gain)). For each 
attribute, three levels were agreed (figure 1). 
 
The patient profile (possibly influencing treatment choices) was selected to imply a clear need for change 
in the treatment and a decisional problem in terms of balancing previously agreed attributes. The patient 
profile allowed for a switch to expensive (biological) medications in the majority of countries to ensure 
respondents do not feel intuitively restricted in their decision by local health care regulations. The agreed 
profile described a patient with anti-citrulline antibody positive RA and moderate disease activity despite 
two conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). The full patient profile 
(online supplementary table S1) has been approved by experts and rheumatologists 
 
Experimental design  
Based on the attributes and levels there are 243 (35) possible treatment combinations - too many to ask 
each rheumatologist to evaluate [24]. We reduce the number of choice sets using a Bayesian efficient 
experimental design (Ngene software [25]). A Bayesian design aims to maximize precision of estimated 
parameters for a given number of choice questions [26] by incorporating a priori information about sign 
and value of parameters. The a priori information was gained from a preliminary DCE with 10 
rheumatologists. Implausible or unrealistic treatment options were excluded from the design (e.g. efficacy 
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is low, costs are high, but the CE is best). In addition three choice sets were included to test if 
respondents made sensible choices. 1. a dominance test – a choice set with one treatment option that is 
clearly better the other; and 2. two repeated choices – choice sets that repeat earlier choices to assess 
the stability of respondents´ choices. A total of 17 choice sets were included in the questionnaire. An 
example of a choice set is shown in figure 1.  
 
The questionnaire 
The questionnaire consisted of two parts – 1. the DCE task and 2. questions collecting socio-demographic 
data (e.g. age, gender, work environment) to facilitate interpretation of the results. The full questionnaire 
was piloted among rheumatologists (n=14) from two different countries to ensure that choice sets, 
attributes and levels were relevant, clear and plausible across countries. Economic attributes were 
presented in local currencies [27]. An online survey was distributed by email through a national principle 
investigator (PI) per country. 
 
Country selection  
As attitudes of rheumatologists may be influenced by external factors like the country´s culture, wealth or 
health care environment, countries from all geographic regions in Europe were invited:  Belgium (BE), 
France (FR); Germany (GE), Hungary (HU), Italy (IT), Netherlands (NL) Norway (NO), Portugal (PT), 
Romania (RO), Spain (SP), Sweden (SE) and United Kingdom (UK).  
 
Statistical analysis 
A rheumatologists responses were considered for data analyses when at least 50% of choice sets were 
completed and they successfully passed the dominance test. A three-step approach was used to analyse 
data. 
 
First, a mixed logit (ML) model was used to assess the relative importance of attributes, using Nlogit, 
version 5 [28].  The following utility model was estimated:  
Uij = β0 + (β1 + ɳ1i) Good response + (β2+ ɳ2i) Remission + (β3+ ɳ3i) Rare AE +  
(β4+ ɳ4i) Uncommon AE + (β5+ ɳ5i) Favoured preference + (β6+ ɳ6i) Disfavoured preference +  
(β7+ ɳ7i) Cost-effectiveness + (β8+ ɳ8i) Costs  
 
U represents the observable relative preference of rheumatologist (i) for a treatment choice (j) which can 
be defined as a sum of preference scores for attributes/levels. β0 is the constant, β1-8 are the mean 
attribute utility weights (physician’s preferences) for the respective attribute and ɳi represents  the random 
parameter for rheumatologist i. Dummy coding was used to describe variables β1-6. Reference categories 
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for efficacy, safety and patient´s preference were moderate response, very rare adverse events and 
neutral patient attitude, respectively. The signs of the β coefficients indicate whether the attribute has a 
negative or positive effect on the rheumatologists’ preference. A ML model allows model parameters to 
vary between respondents, which is reflected in the random parameter. If the standard deviation (SD) of 
this random parameter is significantly different from zero, this is interpreted as evidence of significant 
preference variation for the attribute within the population [29]. Results were considered significant for 
p<0.05.  
 
The relative importance of attributes was calculated based on the range of the level coefficients per 
attribute. using the method described by Malhotra and Birks [30]. More specifically, the relative importance 
weights were derived by dividing the range of the level coefficients for one attribute by the sum of ranges 
of coefficients of all attributes.  
 
Second, to assess potential similarities, countries were grouped on the basis of their similarity in mean 
relative importance weights across the five attributes. Hierarchical Ward´s linkage with a squared 
Euclidean distance measure was used (using STATA version 12 [31]). To determine the optimal cluster 
number, a second clustering method (k-means) was applied and results were compared to hierarchical 
Ward´s linkage to verify if cluster structures were reproducible. Introduction of additional clusters was 
stopped where both clustering methods provided different results. Further we based the decision on 
numbers of clusters on the rule of thumb suggesting 𝑘~√(𝑛/2),  with k describing the number of 
suggested clusters and the number of observations. 
 
Third, a latent class model (LCM, using Nlogit) was used to determine preference profiles of all individual 
rheumatologists. LCM can be used to identify the existence of and the number of classes in the population 
based on their treatment preferences. The LCM can also be used to explore if covariates (such as clusters 
of countries) influence the probability to belong to a particular class. Class membership is latent in that 
each respondent belongs to each class up to a modelled probability [32].  In order to determine the number 
of classes, we selected the model with the best fit based on the Akaike information criterion. To further 
understand the role of country, previously developed country clusters were added as covariate to the 
latent class model in an additional step. Statistically significant parameter estimates (p<0.05) indicate that the 
covariate (i.e. the dummy of country-cluster) contributes to the explanation of latent classes. For example, if 
the parameter estimate for the covariate “country cluster” is positive and significant for a certain class, it 
indicates that rheumatologists from the countries that belong to the country cluster are more likely to 
belong to that particular class.  
 
Results 
Respondent’s socio-demographic characteristics 
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Overall 559 rheumatologists from 12 European countries were included in the analysis. Mean age was 
48.0 years and 49% of rheumatologists were females (table 1). Test- retest reliability was in line with 
existing literature [29] with 82.3% (re-test 1) and 80.8% (re-test 2) of respondents having chosen the same 
alternative in the test–retests. Five respondents failed in the dominance test and were therefore excluded 
from the analysis. 
 
Attribute preferences when selecting a new treatment, overall and at a country-level 
The main results of the MLmodel are summarized in table 2a (coefficients) and 2b (relative importance) for 
all countries and each country separately. The detailed results overall and per country from ML models 
can be extracted from online supplementary table S2.  
Coefficients (table 2a) revealed, that in all countries good response and especially remission were 
significantly more desirable than moderate response (βremission>βgood response). When coefficients were 
significant, probability of a serious adverse event decreased preference for that given treatment option 
(βuncommon<βrare). The patient´s agreement with the treatment was universally associated with an increased 
preference and a stronger, negative impact on preference was seen when patients dislike treatments 
(|βdisagreement|>|βagreement|).The contribution of patient´s disagreement with a treatment choice was significant 
in all countries. The economic aspect also played an important role. Higher economic burden was 
consistently associated with decreased preference. CE was not significant in three countries (FR, IT, RO), 
medication costs however were significant in all countries. 
When comparing contribution of different attributes across countries (table 2b), results revealed that 
efficacy dominated the treatment choice in all countries with comparatively low variations between 
countries (range 39-52%). High variability was observed for the relative contribution of safety (range 1-
20%) whereas patient´s preference played role in all countries (range 7-21%). Similarly, absolute costs 
played a role in all countries (range10-24%) whereas contribution of CE varied importantly with several 
countries largely disregarding CE (range 4-21%). In the majority of countries absolute costs were more 
important than relative CE considerations. 
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Cluster of countries according to the preference profile 
Two clusters were identified (table 2). In cluster 1 (BE, GE, HU, NL, NO, SE, SP, UK) all attributes, except 
safety, had a relevant contribution to treatments choice. In cluster 2 including (FR, IT, PT RO), there was a 
higher emphasis on safety (range 18-20%) and lower emphasis on relative CE considerations (range 3-8 
%).  
 
Classes of individual rheumatologists according to the preference profile 
Four classes of rheumatologists have been identified according to their preference profile (table 3).In all 
classes, efficacy (both levels) and patient´s disagreement with a treatment were significant determinants 
of treatment choice. In class 1, rheumatologists accounted for both economic attributes (absolute costs 
and relative CE) but largely disregarded safety. Overall, 43% of rheumatologists were estimated to belong 
to class 1. Rheumatologists belonging to one of the remaining classes 2-4 disregarded ICER.  
Respondents of class 3 balanced safety and total medication costs, while those in class 2 and 4 
accounted only for either safety (class 2) or total medication costs (class 4) 
. The probabilities to belong to classes 2, 3 and 4 were estimated with 22.6%, 31.1% and 11.1% 
respectively. Rheumatologists from country cluster 2 (FR, IT, PT RO) were significantly more likely to be 
located in classes 2, 3 and 4, with CE playing a minor role. 
 
Discussion  
The study revealed that across countries rheumatologists are willing to trade-off efficacy against patients´ 
preferences and/or economic aspects in treatment choices. 43% of rheumatologists balanced all 
attributes, including CE when choosing a therapy, while for all other rheumatologists, CE did not play a 
substantial role. Medication costs however remained relevant for 77% of clinicians. Two groups of 
countries could be distinguished. One group, which represented the majority of countries, was more likely 
to balance all treatment attributes including CE, while the other group placed little emphasis on CE. 
 
In all countries, rheumatologists considered economic, indicating that rheumatologists support efficient 
use of limited health care resources. However, latent class analyses showed that about half of individual 
rheumatologists are estimated to largely disregard the CE. This can be explained by clinicians having 
limited access to CE data of relevant drugs or methodological complexities and weaknesses in existing 
data [33, 34]. Given the importance of ICER, we need to ensure that trustful and comparable good quality 
data are provided to clinicians to support its use in clinical decision making. In addition,  the direct health 
care environment often rather supports economic trade-offs based on absolute costs [35] even though CE 
data provide more valuable information on efficient treatment choices for society. The present findings 
confirmed that in UK CE and more specifically ICER plays a more decisive role in reimbursement 
decisions compared to many other European countries [36].Of note, CE studies are frequently limited to 
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selected countries although transferability of data across countries is not always possible, further limiting 
its use [33].  
Patients´ preferences were taken into account by all rheumatologists, despite variations observed among 
individuals and between countries. Cultural differences in the physician-patient relationship or the 
physician´s attitude may partly explain the differences. A recent review e.g. found that clinicians are more 
likely to support shared-decision making when their direct work environment supports the concept [1]. 
Interestingly however, rheumatologists from all countries considered in particular patient´s disagreement, 
possibly to avoid poor drug adherence. Although perception towards shared decision making can vary, 
this study for the first time revealed consensus among individuals and across countries on the importance 
of a patient´s disagreement, and is the first to address patient´s preferences in the context of other 
treatment attributes.  
Some limitations have to be considered for interpretation of results. First, the sample size was lower in 
some countries and differences in socio-demographics across countries were observed, thus selection 
bias and limitations in generalizability of results cannot be excluded.  Sub-group analyses of the results 
from NL (results not reported), revealed no significant differences in preferences for different sub-groups. 
Further an efficient experimental design was developed to optimize response efficiency. Second, 
pharmaceutical industry [37] or local health care regulations (in particular the reimbursement criteria) may 
influence the preferences. However, most participating countries do not restrict access to expensive drugs 
for patients described in the DCE, therefore this type of effect is likely limited to countries with very strict 
criteria (UK, HU and RO). Third, although the presented attributes were confirmed as most relevant for 
treatment decisions in RA and a strong methodology was used to select and defined attributes, it cannot 
be excluded that further attributes play a role in some countries. Further research could contribute to a 
better understanding on other relevant factors across European countries. Fourth, presenting two 
economic attributes – costs and CE - in the DCE has it´s limitation as also absolute costs together with 
efficacy and safety provide insights into CE of a drug. However, only including both economic attributes 
allowed to raise awareness on the fact that clinicians are still predominantly focused on costs.  
Finally, this study provides only insight into stated preferences. It remains unknown whether 
rheumatologists reach decisions in the same way in clinical practice as they state in the theoretical 
framework of the DCE. Also, in clinical reality however decisional problems may exceed the complexity 
reflected in the study design. Revealed preferences would be additionally informative, however design and 
execution of such a study would be very difficult.  
 
Despite limitations, this study reveals that values rheumatologists attach to treatment characteristics vary 
importantly between countries and among individual rheumatologists. The complexity of today´s treatment 
decisions justifies more research on behavior of prescribers, as the clinicians’ attitude is one important 
factor contributing to quality and equality in healthcare. We hope the current study will raise awareness on 
the importance of physicians’ behaviors and open discussion on how clinicians are expected to trade-off 
various aspects of a treatment decision. 
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Conclusion 
Overall, rheumatologists take efforts to balance multiple aspects of a treatment choice including the 
patient´s potential disagreement and the economic consequences. However important differences in the 
assessment of economic aspects were observed between and within countries. In most countries 
clinicians still focus on absolute costs while CE would provide more valuable information on the societal 
consequences of a decision.  
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Tables and Figures 
 
 
Table 1: Characteristics of rheumatologists for the total group and each country separately 
 Gender 
 
Age  
 
Work environment  
 
 nfemale/noverall  
(% female) 
years ± SD nacademic/noverall 
(%) academic setting 
 Belgium   (n=33) 16/32 (53%) 41.4 ± 8.0 16/32 (53%) 
 France   (n=40) 21/38 (55%) 51.7 ± 10.6   2/38   (5%) 
 Germany   (n=44) 16/43 (37%) 49.3 ± 8.9   8/43 (19%) 
 Hungary   (n=71) 48/70 (69%) 50.6 ± 11.1 34/70 (49%) 
 Italy   (n=59) 20/57 (35%) 44.0 ± 11.4 31/57 (54%) 
 Netherlands  (n=63) 28/63 (44%) 48.9 ± 7.6 21/63 (33%) 
 Norway   (n=41) 22/39 (56%) 47.6 ± 10.2 17/39 (44%) 
 Portugal   (n=39) 19/36 (53%) 46.7 ± 12.8 11/36 (31%) 
 Romania   (n=42) 25/42 (59%) 43.3 ± 9.2 20/42 (48%) 
 Sweden   (n=24) 16/24 (67%) 50.5 ± 9.7 18/24 (75%) 
 Spain   (n=63) 31/62 (50%) 48.1 ± 8.3 54/62 (87%) 
 United Kingdom  (n=40) 9/40 (23%) 53.5 ± 8.1 34/40 (85%) 
All countries   (n=559) 267/546 (49%) 48.0 ± 10.1 266/546 (49 %) 
N= number of responses, SD= standard deviation 
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Figure 1: Attributes and levels and example choice set of DCE experiment 
 
(a) Attributes and levels describing drug treatment options in DCE experiment  
 
ATTRIBUTES AND ATTRIBUTE 
DEFINITIONS 
ATTRIBUTE LEVELS LEVEL DESCRIPTIONS 
Efficacy 
*Improvement and status of disease 
activity based on DAS28 
1. Good DAS28 response – 
remission achieved 
DAS28 improvement by 3.0 points 
Achievement of remission (DAS28<2.6) 
2. Good DAS 28 response – low 
disease activity achieved  
DAS28 improvement by 2.0 points 
Achievement of low disease activity  
(2.6<DAS28≤ 3.2) 
3. Moderate DAS28 response 
 
DAS28 improvement by 1.0 point 
Low disease activity or remission cannot 
be achieved (DAS28 remains >3.2) 
Safety 
Probability of a serious adverse 
event 
1. Very rare 
2. Rare 
3. Uncommon  
5 out of 100,000 patients 
5 out of 10,000 patients 
5 out of 1,000 patients 
Patient´s Preference  
patient expressed level of 
agreement with treatment choice  
1. Treatment favoured 
2.  Neutral 
3. Treatment disfavoured 
 
Cost-effectiveness  
** ICER, in costs per QALY gained 
 
1. Favourable 
2. Moderate  
3. Unfavourable  
15,000 €/QALY  
30,000 €/QALY 
75,000 €/QALY 
Overall medication costs  
Per year, in local currency 
1. Low  
2. Medium  
3. High  
     800 EUR/year 
  8,000 EUR/year 
14,000 EUR//year 
 
 (b) Example choice set - repeated 17 times with varying attribute levels 
EXAMPLE CHOICE SET TREATMENT A TREATMENT B 
Improvement of DAS28 disease 
activity  
Good response –  
Low disease activity achieved  
 
DAS28 improved from 4.6 to 2.6 
 SCJ improved from 5 to 2 
 TJC improved from 5 to 2 
 ESR improved from 18 to 4 
 PGA improved from 49 to 29 
Good response –  
remission achieved  
 
DAS28 improved from 4.6 to 1.6 
 SCJ improved from 5 to 1 
 TJC improved from 5 to 1 
 ESR improved from 18 to 2 
 PGA improved from 49 to 19 
Risk of serious adverse events  Rare – 
5 patients out of 10,000 patients 
Uncommon –  
5 patients out of 1,000 patients 
Patient´s preference The patient disfavours treatment The patient favours treatment 
Cost-effectiveness Unfavourable –  
75,000 EUR/QALY 
Moderate –  
30,000 EUR/QALY 
Medication costs High –  
14,000 EUR/year 
High –  
14,000 EUR/year 
 
Which treatment would you choose 
for the patient? 
 
Treatment A Treatment B 
X 
In the example choice set the respondent preferred treatment B over treatment A when choosing a drug treatment 
for a patient with moderate disease activity  
 
DCE=discrete choice experiment, DAS28=disease activity core 28; ICER =incremental cost effectiveness ratio, QALY=quality-adjusted life year  
* In the choice sets, also changes of the individual DAS28 components (tender joint count (TJC), swollen joint count (SJC), erythrocyte sedimentation rate (ESR), patient global 
assessment of disease activity (PGA)) were presented  see figure 1 
** ICER is expressed in costs (€) per QALY gained for the selected treatment compared to usual care 
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Table 2: Results from the Discrete Choice Experiment 
a) Results from the Random Parameters Logit Model (β coefficients per attribute level reflecting physician’s preferences for the respective 
attribute) 
          Country/N 
 
Treatment 
Attribute/Level 
BE 
 
 
NO 
 
 
GE 
 
 
SE 
 
 
NL 
 
 
UK 
 
 
HU 
 
 
SP 
 
 
FR 
 
 
IT 
 
 
PT 
 
 
RO 
 
 
All 
countries 
 
33 41 44 24 63 40 71 63 40 59 39 42 559 
Efficacy   
Moderate response Reference level (efficacy) 
Good response 2.08*** 2.93*** 2.93*** 2.81*** 2.40*** 1.92*** 2.31*** 3.33*** 2.49*** 2.41*** 3.40*** 4.96*** 2.30*** 
Remission 3.55*** 4.32*** 5.44*** 5.05*** 4.40*** 3.47*** 4.34*** 5.35*** 3.90*** 4.66*** 5.07*** 8.86*** 3.91*** 
Safety  
Very rare  Reference level (safety) 
Rare -0.37 -0.30 -0.65** -0.82** 0.14 0.00 -0.41** -0.16 -0.61*** -0.89*** -1.14*** -1.15** -0.41*** 
Uncommon -0.97*** -1.04*** -1.21*** -1.28*** 0.05 -0.19 -1.13*** -1.13*** -1.78*** -1.75*** -2.49*** -3.31*** -1.04*** 
Patient´s preference  
Patient favours treatment 0.17 0.24 0.57** 0.47 0.29* 0.44** 0.62** 0.71*** 0.53** 0.49*** 0.00 0.04 0.40*** 
Patient is neutral Reference level (patient´s preference) 
Patient disfavours treatment -0.84*** -1.27*** -1.28*** -1.75*** -1.45*** -1.22*** -0.87*** -1.44*** -1.40*** -0.97*** -1.69*** -1.12** -1.03*** 
 Cost-effectiveness (10,000 
EUR/QALY) 
-0.15*** -0.21*** -0.03*** -0.19*** -0.23*** -0.31*** -0.22*** -0.21*** -0.05 -0.14 -0.18** -0.11 -0.15*** 
Overall medication costs 
(1,000 EUR/year) 
-0.12*** -0.19*** -0.19*** -0.15*** -0.18*** -0.14*** -0.09*** -0.16*** -0.09*** -0.12*** -0.19*** -0.23*** -0.12*** 
Constant 0.14 -0.15 -0.40** -0.30 -0.26** -0.32** -0.15 0.02 -0.16 -0.31** -0.24 -0.57 -0.15*** 
McFadden Pseudo R-
squared (R2). 0.61 0.65 0.66 0.67 0.46 0.63 0.63 0.65 0.58 0.63 0.64 0.63 0.39 
BE=Belgium, FR=France, GE=Germany, HU=Hungary, IT=Italy, NL=Netherlands, NO=Norway, PT=Portugal, RO=Romania, SE=Sweden, SP=Spain, N= number of responses per country and overall,  
*** significant at 1%, ** significant at 5%, * significant at 10%,  
All parameters were included as random parameters and assumed to be normally distributed. The estimation was conducted using 1000 Halton draws.
15 
 
 
b) Contribution of each of the treatment attributes to the overall preference for a treatment choice 
(mean per country, in percent (%) of total explained variance) 
 
Country/N 
 
Treatment 
Attribute 
BE 
 
 
NO 
 
 
GE 
 
 
SE 
 
 
NL 
 
 
UK 
 
 
HU 
 
 
SP 
 
 
FR 
 
 
IT 
 
 
PT 
 
 
RO 
 
 
All 
countries 
 
33 41 44 24 63 40 71 63 40 59 39 42 559 
Country Clusters Country Cluster 1 Country Cluster 2  
Efficacy 
Improvement 
DAS28 
44% 40% 42% 43% 44% 39% 46% 45% 43% 45% 39% 52% 44% 
Safety 
Probability of a 
serious AE 
10% 10% 9% 11% 1% 2% 12% 10% 20% 18% 19% 19% 12% 
Patient´s 
Preference 
14% 14% 14% 19% 17% 19% 16% 18% 21% 14% 14% 7% 16% 
Cost-
Effectiveness 
ICER, QALY/year 
9% 12% 14% 10% 14% 21% 14% 10% 3% 8% 8% 4% 10% 
Medication costs 
per year, in local 
currency 
23% 24% 19% 17% 24% 19% 12% 17% 13% 15% 20% 18% 18% 
Model fit, R2 0.61 0.65 0.66 0.67 0.46 0.63 0.63 0.65 0.58 0.63 0.64 0.63 0.39 
BE=Belgium, FR=France, GE=Germany, HU=Hungary, IT=Italy, NL=Netherlands, NO=Norway, PT=Portugal, RO=Romania, SE=Sweden, SP=Spain, N= number of responses per 
country and overall, DAS28= Disease Activity Score in 28 joints, AE=Adverse Event, ICER=Incremental Cost-Effectiveness Ratio, n.a.=not applicable, R2=McFadden Pseudo R-squared 
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Table 3: Results latent class model distinguished 4 classes of respondents.  
Latent class model 
(Responder type) 
 
Latent class 1 
 
All attributes (except 
safety) balanced 
Latent class 2 
 
Emphasis on efficacy, 
safety and patient´s 
preference, economic 
aspects less relevant, 
Latent class 3 
 
All attributes except cost-
effectiveness balanced 
Latent class 4  
 
Emphasize on efficacy, 
patient dislike and costs 
Average class 
probability 1) 
43.2 % 
 
22.6% 
 
23.1 % 
 
11.1 % 
 
Efficacy  
Moderate response 
Good response 
Remission 
 
Reference level 
1.98*** 
3.08*** 
 
Reference level 
3.65*** 
6.39*** 
 
Reference level 
2.32*** 
3.38*** 
 
Reference level 
1.74*** 
3.85*** 
Safety 
Very rare  
Rare  
Uncommon 
 
Reference level 
 0.09 
-0.07 
 
Reference level 
-1.38* 
-2.71*** 
 
Reference level 
-0.96*** 
-2.45*** 
 
Reference level 
-0.44 
-0.58* 
Patient´s preference 
favours treatment 
neutral 
disfavours treatment 
 
0.33***  
Reference level 
-0.84*** 
 
2.35*** 
Reference level 
1.53*** 
 
-0.37**  
Reference level 
-1.34*** 
 
0.53 
Reference level 
-3.17*** 
Cost-effectiveness  
(10,000 EUR/QALY) 
-0.29*** -0.28* -0.03 -0.07 
Overall medication 
costs (1000 EUR/year) 
 0.13** -0.02 -0.11*** -0.09*** 
Constant  0.02 -1.64*** -0.22** -0.34 
Class probability model 
-  cluster 2 2)  
_____  1.41*** 2.09*** 1.16* 
 *** significant at 1%, ** significant at 5%, * significant at 10%,  
1) Average class probability = Probability that individual respondent chooses drug treatments according to respective responder types (all 559 responses from 12 countries 
included in the analysis) 
2) Parameter estimates indicate that rheumatologists belonging to country cluster 2 (consisting of Romania, France, Portugal and Italy) compared to country cluster 1 
(reference) are significantly more likely to be in classes 2, 3 or 4. 
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